学術情報 -AJRCCM(ブルージャーナル)-

本誌は、American Thoracic Society(米国胸部学会)の発行するAmerican Journal of Respiratory and Critical Care Medicineをもとに、シュプリンガー・ジャパン株式会社が公正中立の立場で論文選択、翻訳等を含む作業全般を担っている医療関係者向けの資材です。

弊社は、医療関係者に有益な情報を提供することを通じて医療に貢献することを目的に本資材の提供を行っており、本資材作成にかかる費用を負担しています。

本資材には本邦における未承認の医薬品、効能・効果及び用法・用量等の情報が含まれる場合がありますが、これを推奨するものではありません。

本資材を受領される際には、以下の内容をご確認いただきたく存じます。

  • 本資材に記載された薬剤の使用にあたっては、最新の添付文書をご参照ください。
  • 本資材は医療関係者からの求めに応じて提供するものであり、企業が積極的に提供するものではありません。

2018年10月 -PART 02-

アルモダフィニル(Armodafinil)は睡眠時無呼吸症候群患者の自動車運転能及び体重減少を改善するか?無作為化試験の成績

Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial Am J Respir Crit Care Med 2018; 198(7): 941-950

慢性閉塞性肺疾患(COPD)におけるオプソニン貪食作用はNrf2アゴニストにより増強される

Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists Am J Respir Crit Care Med 2018; 198(6): 739-750

微粒子物質による大気汚染レベルの短期上昇と急性下気道感染症

Short-Term Elevation of Fine Particulate Matter Air Pollution and Acute Lower Respiratory Infection Am J Respir Crit Care Med 2018; 198(6): 759-766

2018年10月 -PART 01-

切除可能な非小細胞肺癌における血中及び腫瘍中の骨髄由来免疫抑制細胞

Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer Am J Respir Crit Care Med 2018; 198(6): 777-787

慢性喘息モデルにおける吸入インターロイキン13抗体フラグメントの有効性

Efficacy of an Inhaled IL-13 Antibody Fragment in a Model of Chronic Asthma Am J Respir Crit Care Med 2018; 198(5): 610-619

プライマリケア医師は睡眠時無呼吸患者の総合的管理が可能である:非劣性無作為化比較試験

Primary Care Physicians Can Comprehensively Manage Patients with Sleep Apnea A Noninferiority Randomized Controlled Trial Am J Respir Crit Care Med 2018; 198(5): 648-656

Selected articles from AJRCCM. Copyright 2018 by the American Thoracic Society. All rights reserved. The ideas and opinions expressed in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) or other associated publications do not necessarily reflect those of the American Thoracic Society (ATS). The authors, editors or ATS are not responsible for errors or omissions of articles published in print or online from AJRCCM or other associated ATS publications. Although great care has been taken in compiling the content of this publication, neither ATS or their servants are responsible or liable in any way for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising there from. Approved product information should be reviewed before prescribing. The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ATS assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. 

The translation is © 2018 American Thoracic Society. American Thoracic Society or Springer Healthcare takes no responsibility for the accuracy of the translation from the published English original and are not liable for any errors that may occur.